Swertisin, a plant-derived C-glucosylflavone, is known to have antidiabetic, anti-inflammatory and antioxidant effects. In the present study, we investigated in mice the effects of swertisin on glutamatergic dysfunction induced by dizocilpine (MK-801), a non-competitive N-methyl-D-aspartate receptor antagonist. In the Acoustic Startle Response test, their MK-801-induced (given 0.2 mg/kg i.p.) pre-pulse inhibition deficit was significantly attenuated by the administration of swertisin (30 mg/kg p.o.). In the Novel Object Recognition Test, the recognition memory impairments that were induced by MK-801 (0.2 mg/kg, given i.p.) were also reversed by administration of swertisin (30 mg/kg p.o.). In addition, swertisin normalized the MK-801-induced elevation of phosphorylation levels of Akt and GSK-3β signaling molecules in the prefrontal cortex. These results indicated that swertisin may be useful in managing the symptoms of schizophrenia, including sensorimotor gating disruption and cognitive impairment, and that these behavioral outcomes may be related to Akt-GSK-3β signaling in the prefrontal cortex.
AbekawaTItoKNakagawaS. (2011) Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents. Schizophren Res125: 77–87.
2.
AhnYMSeoMSKimSH. (2005) Increased phosphorylation of Ser473-Akt, Ser9-GSK-3beta and Ser133-CREB in the rat frontal cortex after MK-801 intraperitoneal injection. Int J Neuropsychopharmacol8: 607–613.
3.
AlimohamadHRajakumarNSeahYH. (2005) Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry57: 533–542.
4.
AquilaSGinerRMRecioMC. (2009) Anti-inflammatory activity of flavonoids from Cayaponia tayuya roots. J Ethnopharmacol121: 333–337.
5.
BardinLKlevenMSBarret-GrevozC. (2006) Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology31: 1869–1879.
6.
BellRLRoddZAHsuCC. (2003) Amphetamine-modified acoustic startle responding and prepulse inhibition in adult and adolescent alcohol-preferring and -nonpreferring rats. Pharmacol Biochem Behav75: 163–171.
7.
ChengGBaiYZhaoY. (2000) Flavonoids from Ziziphus jujuba Mill var. spinosa. Tetrahedron56: 8915–8920.
8.
DadheechNSrivastavaAParanjapeN. (2015) Swertisin an anti-diabetic compound facilitates islet neogenesis from sancreatic Stem/progenitor cells via p-38 MAP kinase-SMAD pathway: An in-vitro and in-vivo study. PLoS ONE10: e0128244.
9.
DobleBWWoodgettJR (2003) GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci116: 1175–1186.
10.
EggersAE (2013) A serotonin hypothesis of schizophrenia. Med Hypotheses80: 791–794.
11.
EmamianES (2012) AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci5: 33.
12.
EmamianESHallDBirnbaumMJ. (2004) Convergent evidence for impaired AKT1-GSK3-beta signaling in schizophrenia. Nat Genet36: 131–137.
13.
FoladorPCazarolliLHGazolaAC. (2010) Potential insulin secretagogue effects of isovitexin and swertisin isolated from Wilbrandia ebracteata roots in non-diabetic rats. Fitoterapia81: 1180–1187.
14.
FranklandPWWangYRosnerB. (2004) Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol Psychiatry9: 417–425.
15.
FreybergZFerrandoSJJavitchJA (2010) Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry167: 388–396.
16.
GobiraPHRopkeJAguiarDC. (2013) Animal models for predicting the efficacy and side effects of antipsychotic drugs. Rev Bras Psiquiatr35: S132–S139.
17.
GuestPCIwataKKatoTA. (2015) MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: Insights for schizophrenia. Front Cell Neurosci9: 180.
18.
HashimotoKMalchowBFalkaiP. (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci263: 367–377.
19.
HesslDBerry-KravisECordeiroL. (2009) Prepulse inhibition in fragile X syndrome: feasibility, reliability and implications for treatment. Am J Med Genet B Neuropsychiatr Genet150B: 545–553.
20.
HoBAndreasenNCZiebellS. (2011) Long-term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry68: 128–137.
21.
HowesODKapurS (2009) The dopamine hypothesis of schizophrenia: Version III. The final common pathway. Schizophr Bull35: 549–562.
22.
JungIHLeeHEParkSJ. (2014) Ameliorating effect of spinosin, a C-glycoside flavonoid, on scopolamine-induced memory impairment in mice. Pharmacol Biochem Behav120: 88–94.
23.
KapurSRemingtonG (2001) Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annu Rev Med52: 503–517.
24.
KimDHJeonSJSonKH. (2006) Effect of the flavonoid oroxylin A on transient cerebral hypoperfusion-induced memory impairment in mice. Pharmacol Biochem Behav85: 658–668.
25.
KimDHJeonSJSonKH. (2007) The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice. Neurobiol Learn Mem87: 536–546.
26.
KimDHKimSJeonSJ. (2008) The effects of acute and repeated oroxylin A treatments on Abeta(25–35)-induced memory impairment in mice. Neuropharmacology55: 639–647.
27.
KimuraYSumiyoshiM (2011) Effects of Swertia japonica extract and its main compound swertiamarin on gastric emptying and gastrointestinal motility in mice. Fitoterapia82: 827–833.
28.
KirkpatrickBFentonWSCarpenterWTJr. (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull32: 214–219.
29.
KorosEDorner-CiossekC (2007) The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect20: 437–445.
30.
LahtiACWeilerMATamara MichaelidisBA. (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology25: 455–467.
31.
LeeHEJeonSJRyuB. (2016) Swertisin, a C-glucosylflavone, ameliorates scopolamine-induced memory impairment in mice with its adenosine A1 receptor antagonistic property. Behav Brain Res306: 137–145.
32.
LeuchtSPitschel-WalzGAbrahamD. (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole, compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res35: 51–68.
33.
LiXRosboroughKMFriedmanAB. (2007) Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol10: 7–19.
34.
LindenmayerJ-PCzoborPVolavkaJ. (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry160: 290–296.
35.
LudewigSLudewigKGeyerMA. (2002) Prepulse inhibition deficits in patients with panic disorder. Depress Anxiety15: 55–60.
36.
MahmoodDAkhtarMJahanK. (2016) Histamine H3 receptor antagonists display antischizophrenic activities in rats treated with MK-801. J Basic Clin Physiol Pharmacol27: 463–471.
37.
MeinckeULightGAGeyerMA. (2004) Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res126: 51–61.
38.
MeltzerHY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology99: S18–S27.
39.
MoghaddamBJavittD (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology37: 4–15.
PerryWMinassianAFeifelD. (2001) Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry50: 418–424.
43.
PerryWMinassianALopezB. (2007) Sensorimotor gating deficits in adults with autism. Biol Psychiatry61: 482–6.
44.
RompalaGRZsirosVZhangS. (2013) Contribution of NMDA receptor hypofunction in prefrontal and cortical excitatory neurons to schizophrenia-like phenotypes. PLoS ONE8: e61278.
45.
RossCAMargolisRLReadingSAJ. (2006) Neurobiology of schizophrenia. Neuron52: 139–53.
46.
SongGOuyangGBaoS (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med9: 59–71.
47.
SwerdlowNRBenbowCHZisookS. (1993) A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry33: 298–301.
48.
SwerdlowNRKarbanBPloumY. (2001) Tactile prepuff inhibition of startle in children with Tourette’s syndrome: in search of an “fMRI-friendly” startle paradigm. Biol Psychiatry50: 578–85.
49.
SwerdlowNRPaulsenJBraffDL. (1995) Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington’s disease. J Neurol Neurosurg Psychiatry58: 192–200.
50.
TrampushJWLenczTDeRosseP. (2015) Relationship of cognition to clinical response in first-episode schizophrenia spectrum disorders. Schizophr Bull41: 1237–47.
51.
ZhengWWangHZengZ. (2012) The possible role of the Akt signaling pathway in schizophrenia. Brain Res1470: 145–58.
52.
ZinkMEnglischSSchmittA (2014) Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. Eur Arch Psychiatry Clin Neurosci264: S67–S82.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
